ReviewInternational journal of molecular sciences2023
Autoantibodies in Atrial Fibrillation-State of the Art.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A Review on the Role of Oral Bacteria in Stroke.International journal of molecular sciences · 2025Review
- Antinuclear antibodies as a risk factor for ischemic stroke or death in elderly patients with atrial fibrillation despite anticoagulation.Clinical rheumatology · 2025Article
- Autoimmune antibodies in arrhythmia: a narrative review of potential therapeutic targets to prevent overtreatment.Cardiovascular diagnosis and therapy · 2025Review
- Immune cells and arrhythmias.Cardiovascular research · 2025Review
- Critical Challenges in Cancer Immunotherapy and Cardiac Health.Current cardiology reviews · 2025Review
- Pioglitazone Alleviates β1-adrenergic Receptor Antibody-induced Atrial Fibrillation SusceptivityCurrent medicinal chemistry · 2025Article
- Article
- Article
- Advances in Molecular and Translational Medicine.International journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. To date, a lot of research has been conducted to investigate the underlying mechanisms of this disease at both molecular and cellular levels. There is increasing evidence suggesting that autoimmunity is an important factor in the initiation and perpetuation of AF. Autoantibodies are thought to play a pivotal role in the regulation of heart rhythm and the conduction system and, therefore, are associated with AF development. In this review, we have summarized current knowledge concerning the role of autoantibodies in AF development as well as their prognostic and predictive value in this disease. The establishment of the autoantibody profile of separate AF patient groups may appear to be crucial in terms of developing novel treatment approaches for those patients; however, the exact role of various autoantibodies in AF is still a matter of ongoing debate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.